Cargando…

Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT

INTRODUCTION: Since allogeneic stem cell transplantation (allo-HSCT) is considered one of the curative treatments for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), hematological relapse following allo-HSCT remained a crucial concern for patients’ survival. METHODS: We retrospectiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Zhangjie, Zhen, Sisi, Zhang, Tingting, Shen, Yuyan, Pang, Aiming, Yang, Donglin, Zhang, Rongli, Ma, Qiaoling, He, Yi, Wei, Jialin, Zhai, Weihua, Chen, Xin, Jiang, Erlie, Han, Mingzhe, Feng, Sizhou
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079210/ https://www.ncbi.nlm.nih.gov/pubmed/37035180 http://dx.doi.org/10.3389/fonc.2023.1137175

Ejemplares similares

P570: VENETOCLAX PLUS HYPOMETHYLATING AGENTS VERSUS INTENSIVE CHEMOTHERAPY FOR HEMATOLOGICAL RELAPSE OF MYELOID MALIGNANCIES AFTER ALLO-HSCT
por: Chen, Zhangjie, et al.
Publicado: (2023)

Efficacy of Recombinant Human Thrombopoietin for the Treatment of Secondary Failure of Platelet Recovery After Allogeneic HSCT
por: Cao, Yigeng, et al.
Publicado: (2022)

Combination treatment of rituximab and donor platelets infusion to reduce donor‐specific anti‐HLA antibodies for stem cells engraftment in haploidentical transplantation
por: Zhang, Rongli, et al.
Publicado: (2020)

The outcome of acute leukemia patients with SET-NUP214 fusion after allogeneic stem cell transplantation
por: Shen, Yuyan, et al.
Publicado: (2023)

The prognostic impact of previously infectious complications on allogeneic hematopoietic stem cell transplantation for patients with severe aplastic anemia: A single-center, retrospective study
por: Zhang, Yuanfeng, et al.
Publicado: (2022)

Cardiac involvement in a patient with B-cell lymphoblastic lymphoma/acute lymphoblastic leukemia and a history of allogeneic hematopoietic stem cell transplantation and CAR T-cell therapy: A case report
por: Cao, Yigeng, et al.
Publicado: (2023)

P1262: GILTERITINIB MAINTENANCE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA WITH FLT3–INTERNAL TANDEM DUPLICATION MUTATION
por: Liang, Chen, et al.
Publicado: (2023)

Intravenous-oral itraconazole versus oral posaconazole in preventing invasive fungal diseases for acute leukemia patients
por: Liu, Li, et al.
Publicado: (2023)

Comparison of characteristics and outcomes on ETP-ALL/LBL and non-ETP ALL patients receiving allogeneic hematopoietic stem cell transplantation
por: Chen, Juan, et al.
Publicado: (2023)

P1273: COMPARISON OF TOTAL BODY IRRADIATION-BASED WITH CHEMOTHERAPY-BASED MYELOABLATIVE CONDITIONING REGIMENS IN PATIENTS WITH B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN FIRST COMPLETE REMISSION
por: Mengnan, LV, et al.
Publicado: (2023)

PB1731: INOTUZUMAB OZOGAMICIN IN LYMPHOID B-CELL MALIGNANCY：A SINGLE CENTER ANALYSIS IN THE REAL WORLD
por: LV, Mengnan, et al.
Publicado: (2023)

Outcome of autologous stem cell transplantation in patients with favorable-risk acute myeloid leukemia in first remission
por: Chen, Juan, et al.
Publicado: (2022)

Comparison of Hematopoietic Stem Cell Transplantation Outcomes Using Matched Sibling Donors, Haploidentical Donors, and Immunosuppressive Therapy for Patients With Acquired Aplastic Anemia
por: Zhang, Yuanfeng, et al.
Publicado: (2022)

Risk factors for CMV infection within 100 days posttransplantation in patients with acute leukemia
por: Chen, Juan, et al.
Publicado: (2022)

Comparison of porcine ALG and rabbit ATG on outcomes of HLA-haploidentical hematopoietic stem cell transplantation for patients with acquired aplastic anemia
por: Chen, Juan, et al.
Publicado: (2022)

Retrospective Comparison of Efficacy and Safety of Rabbit Anti-Thymocyte Globulin and Porcine Anti-Lymphocyte Globulin in Patients With Acquired Aplastic Anemia Undergoing Hematopoietic Stem Cell Transplantation From Matched Sibling Donors
por: Zhang, Yuanfeng, et al.
Publicado: (2022)

CD11c participates in triggering acute graft‐versus‐host disease during bone marrow transplantation
por: Wang, Qianqian, et al.
Publicado: (2021)

Risk factors associated with hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation
por: Shen, Biao, et al.
Publicado: (2022)

PB2411: THE EFFICACY OF MODIFIED MELPHALAN AND BUSULFAN-BASED CONDITIONING REGIMEN FOR AUTOLOGOUS-HSCT IN LOW-RISK AND INTERMEDIATE-RISK AML PATIENTS
por: Zhai, Weihua, et al.
Publicado: (2023)

P1304: TREATMENT WITH COMBINATION OF RITUXIMAB AND INTRAVENOUS Γ GLOBULIN IS EFFECTIVE IN PROMOTING ENGRAFTMENT IN DONOR SPECIFIC ANTIBODY POSITIVE PATIENTS RECEIVING HAPLOIDENTICAL STEM CELL TRANSPLANT
por: Shen, Yuyan, et al.
Publicado: (2023)

Hematopoietic stem cell transplantation from an infected SARS-CoV2 haploidentical donor: A case report
por: Chen, Xin, et al.
Publicado: (2023)

Loss of Lkb1 impairs Treg function and stability to aggravate graft-versus-host disease after bone marrow transplantation
por: Su, Xiuhua, et al.
Publicado: (2019)

Assessment of mortality-related risk factors and effective antimicrobial regimens for treatment of bloodstream infections caused by carbapenem-resistant Pseudomonas aeruginosa in patients with hematological diseases
por: Zhen, Sisi, et al.
Publicado: (2023)

P1527: ASSESSMENT OF RISK FACTORS AND ANTIMICROBIAL THERAPY FOR CARBAPENEM-RESISTANT PSEUDOMONAS AERUGINOSA BLOODSTREAM INFECTIONS IN HEMATOLOGICAL PATIENTS
por: Chen, Zhangjie, et al.
Publicado: (2023)

PB2208: CAR-T TREATMENT POST FIRST ALLO-HSCT FAILURE MAY HAVE DIFFERENT PROCESSION COMPARING TO CAR-T BEFORE ALLO-HSCT
por: wang, D., et al.
Publicado: (2022)

P1290: UPFRONT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION CAN PROVIDE SURVIVAL BENEFIT VERSUS HYPOMETHYLATING AGENT IN MYELODYSPLASTIC SYNDROME WITH INCREASED BLASTS I (MDS-IBI)
por: Runzhi, MA, et al.
Publicado: (2023)

Pre-transplant Rehabilitation to Decrease the Post-transplant Length of Stay for Hematological Malignancy Patients Undergoing Allo-HSCT
por: Matsugaki, Ryutaro, et al.
Publicado: (2021)

P1298: THE EFFICACY AND SAFETY OF MODIFIED MELPHALAN AND BUSULFAN-BASED CONDITIONING REGIMEN FOR ALLOGENEIC-HSCT IN REFRACTORY/RELAPSED OR PERSISTENT MRD POSITIVITY AML PATIENTS
por: Jiang, Erlie, et al.
Publicado: (2023)

Bloodstream infections due to Carbapenem-Resistant Enterobacteriaceae in hematological patients: assessment of risk factors for mortality and treatment options
por: Zhang, Lining, et al.
Publicado: (2023)

Family caregivers’ support needs during allo-HSCT—a longitudinal study
por: Kisch, Annika M., et al.
Publicado: (2020)

Cytokine Overproduction and Immune System Dysregulation in alloHSCT and COVID-19 Patients
por: Lange, Andrzej, et al.
Publicado: (2021)

Influence of CYP2C19 Genotypes on the Occurrence of Adverse Drug Reactions of Voriconazole among Hematological Patients after Allo-HSCT
por: Sienkiewicz, Beata, et al.
Publicado: (2017)

PB2441: CD34+ CELL DOSE EFFECTS ON CLINICAL OUTCOMES OF ALLO-HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT)
por: Zhou, Shengnan, et al.
Publicado: (2023)

Ruxolitinib as an Effective and Steroid-Sparing First-Line Treatment in Newly Diagnosed BOS Patients After Hematopoietic Stem Cell Transplantation
por: Zhang, Xiaoyu, et al.
Publicado: (2022)

Desialylation is associated with apoptosis and phagocytosis of platelets in patients with prolonged isolated thrombocytopenia after allo-HSCT
por: Zhang, Xiao-Hui, et al.
Publicado: (2015)

Development of a Nomogram for Predicting the Cumulative Incidence of Disease Recurrence of AML After Allo-HSCT
por: Zhang, Tongtong, et al.
Publicado: (2021)

Polymyositis as a manifestation of chronic graft‐versus‐host disease after allo‐HSCT
por: Meng, Lijuan, et al.
Publicado: (2018)

Targeting SLP76:ITK interaction separates GVHD from GVL in allo-HSCT
por: Mammadli, Mahinbanu, et al.
Publicado: (2021)

Optimizing autologous hematopoietic stem cell transplantation for acute leukemia
por: Pang, Aiming, et al.
Publicado: (2021)

Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia
por: Saliba, Antoine N., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_oq1hq9cpnu2ktcj2pj2n0ieu9p